Solid Biosciences Inc.

Solid Biosciences Inc.

NNASDAQ:SLDB
6.48
USD
-0.36
(-5.26%)
-1.72EPS
806.54MMarket Cap
Mar 16Next Earn

Total Valuation

USD

As of September 30, 2026, Solid Biosciences Inc. carries a market capitalization of 806.54M, placing it among publicly traded companies globally. Its enterprise value stands at 477.24M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap806.54M
Enterprise Value477.24M

Important Dates

Solid Biosciences Inc.'s next confirmed earnings release is scheduled for March 16, 2027.

Earnings Date3/16/2027

Share Statistics

As of September 30, 2026, Solid Biosciences Inc. has 111.56M shares outstanding.

Shares Outstanding111.56M

Valuation Ratios

These figures are as of September 30, 2026.

PB Ratio2.36
P/TBV Ratio2.36
P/FCF Ratio-4.51
P/OCF Ratio-4.54

Financial Position

As of September 30, 2026, Solid Biosciences Inc. maintains a current ratio of 11.99, meaning it holds 12.0x the short-term assets needed to cover near-term liabilities.

Current Ratio11.99
Quick Ratio11.46
Debt / Equity5.74
Debt / EBITDA-0.09

Financial Efficiency

Over the twelve months ended September 30, 2026, Solid Biosciences Inc. posted a negative return on equity (ROE) of -76.87, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -64.86, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 121.00, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-76.87
Return on Assets (ROA)-64.86
Employee Count121.00

Stock Price Statistics

USD

As of the close on November 16, 2026, Solid Biosciences Inc.'s stock has gained approximately 52.83% over the past 52 weeks. The 50-day moving average sits at 7.12, while the 200-day moving average is 7.68.

52-Week Price Change52.83%
50-Day Moving Average7.12
200-Day Moving Average7.68

Income Statement

USD

Over the twelve months ended September 30, 2026, Solid Biosciences Inc. generated - - in revenue and converted that into -215.27M in net income, yielding earnings per share of -1.72. EBITDA reached -220.08M, while operating income came in at -221.75M.

Operating Income-221.75M
Pretax Income-215.27M
Net Income-215.27M
EBITDA-220.08M
EBIT-221.75M
Earnings Per Share (EPS)-1.72

Balance Sheet

USD

As of September 30, 2026, Solid Biosciences Inc. holds 348.93M in cash and equivalents against 19.62M in total debt, resulting in a net debt position of -125.97M. Total book value stands at 342.11M, with working capital of 334.74M providing operational flexibility.

Cash & Cash Equivalents348.93M
Total Debt19.62M
Net Debt-125.97M
Equity (Book Value)342.11M
Book Value Per Share3.07
Working Capital334.74M

Cash Flow

USD

Solid Biosciences Inc. produced -198.92M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -1.38M in capital expenditures, free cash flow totaled -200.30M - equivalent to -1.60 per share.

Operating Cash Flow-198.92M
Capital Expenditures-1.38M
Free Cash Flow-200.30M
FCF Per Share-1.60

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -22.20: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -38.25, meaning Solid Biosciences Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-38.25
FCF Yield-22.20

Stock Splits

Solid Biosciences Inc.'s most recent stock split took place on October 28, 2022 with a 15:1 split ratio.

Last Split Date10/28/2022
Split Ratio15:1

Scores

As of September 30, 2026, Solid Biosciences Inc. has an Altman Z-Score of 5.25, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score5.25